These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30343508)

  • 41. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
    Schulze-Neick I; Hartenstein P; Li J; Stiller B; Nagdyman N; Hübler M; Butrous G; Petros A; Lange P; Redington AN
    Circulation; 2003 Sep; 108 Suppl 1():II167-73. PubMed ID: 12970227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease.
    Lopes AA; Barreto AC; Maeda NY; Cícero C; Soares RP; Bydlowski SP; Rich S
    Braz J Med Biol Res; 2011 Dec; 44(12):1269-75. PubMed ID: 22068906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension.
    Lopes AA; Maeda NY; Gonçalves RC; Bydlowski SP
    Am Heart J; 2000 Apr; 139(4):618-23. PubMed ID: 10740142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial dual oral combination therapy in pulmonary arterial hypertension.
    Sitbon O; Sattler C; Bertoletti L; Savale L; Cottin V; Jaïs X; De Groote P; Chaouat A; Chabannes C; Bergot E; Bouvaist H; Dauphin C; Bourdin A; Bauer F; Montani D; Humbert M; Simonneau G
    Eur Respir J; 2016 Jun; 47(6):1727-36. PubMed ID: 26989105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral Tadalafil in Children with Pulmonary Arterial Hypertension.
    Shiva A; Shiran M; Rafati M; Zamani H; Babazadeh K; Saeedi M; Ala S
    Drug Res (Stuttg); 2016 Jan; 66(1):7-10. PubMed ID: 25611962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
    Dardi F; Manes A; Palazzini M; Bachetti C; Mazzanti G; Rinaldi A; Albini A; Gotti E; Monti E; Bacchi Reggiani ML; Galiè N
    Eur Respir J; 2015 Aug; 46(2):414-21. PubMed ID: 26022952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Liu LC; Hummel YM; van der Meer P; Berger RM; Damman K; van Veldhuisen DJ; Voors AA; Hoendermis ES
    Eur J Heart Fail; 2017 Jan; 19(1):116-125. PubMed ID: 27873388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of drugs for pediatric pulmonary hypertension.
    Nakau K; Sugimoto M; Oka H; Kajihama A; Maeda J; Yamagishi H; Kamiyama N; Tasaki Y; Kajino H; Azuma H
    Pediatr Int; 2016 Nov; 58(11):1112-1117. PubMed ID: 27038140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparative evaluation of the effect of pipolphen and euphyllin on hemodynamics in congenital heart defects with and without pulmonary hypertension].
    Chepkiĭ LP; Shubin MK; Panichkin IuV; Nikishin LF; Brusan LA
    Kardiologiia; 1971 Feb; 11(2):84-8. PubMed ID: 5568396
    [No Abstract]   [Full Text] [Related]  

  • 50. Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data.
    Yamazaki H; Kobayashi N; Taketsuna M; Tajima K; Murakami M
    Curr Med Res Opin; 2017 May; 33(5):963-971. PubMed ID: 28277870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study.
    Humpl T; Reyes JT; Holtby H; Stephens D; Adatia I
    Circulation; 2005 Jun; 111(24):3274-80. PubMed ID: 15956137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous sildenafil in the management of pulmonary hypertension associated with congenital diaphragmatic hernia.
    Bialkowski A; Moenkemeyer F; Patel N
    Eur J Pediatr Surg; 2015 Apr; 25(2):171-6. PubMed ID: 24163194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
    Blanco I; Gimeno E; Munoz PA; Pizarro S; Gistau C; Rodriguez-Roisin R; Roca J; Barberà JA
    Am J Respir Crit Care Med; 2010 Feb; 181(3):270-8. PubMed ID: 19875684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.
    Hoeper MM; Ewert R; Jansa P; Sirenko Y; Skride A; Balagtas C; Hackley S; Vogt S; Abreu P; Haughie S; Hassan T; Oudiz RJ
    Circulation; 2024 Jun; 149(25):1949-1959. PubMed ID: 38752352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension.
    Bacha NC; Levy M; Guerin CL; Le Bonniec B; Harroche A; Szezepanski I; Renard JM; Gaussem P; Israel-Biet D; Boulanger CM; Smadja DM
    Pediatr Pulmonol; 2019 Jan; 54(1):66-72. PubMed ID: 30485728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
    Guazzi M; Vicenzi M; Arena R
    Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Survival in pulmonary arterial hypertension, associated with connective tissue diseases, treated by sildenafil: results of the prospective study].
    Volkov AV; Nikolaeva EV; Yudkina NN; Kurmukov IA; Nasonov EL
    Ter Arkh; 2015; 87(11):62-67. PubMed ID: 26821419
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.
    Jing ZC; Yu ZX; Shen JY; Wu BX; Xu KF; Zhu XY; Pan L; Zhang ZL; Liu XQ; Zhang YS; Jiang X; Galiè N;
    Am J Respir Crit Care Med; 2011 Jun; 183(12):1723-9. PubMed ID: 21471085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.